WuXi PharmaTech Completes Suzhou Biosafety Testing Facility

WuXi PharmaTech has completed construction of its new biosafety testing facility in Suzhou. The facility has 38,000 sq.-ft. of labs and support areas, and is located next to WuXi’s GLP preclinical drug safety facility. Operations will begin this summer, once validations are completed. Service offerings will include clinical and commercial lot release programs, viral clearance testing, and virus and molecular-based safety detection services for local and multinational customers.
 
“WuXi’s expanding capabilities help our customers advance their biologic product candidates through development more quickly and cost-effectively,” said Dr. Ge Li, chairman and chief executive officer of WuXi PharmaTech. “By investing in capabilities that address our customers’ needs, we have become a leading biologics solution provider.”